Pipeline

Product Development Portfolio

Inflammation

  • Ulcerative Colitis Anti-inflammatory
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX464 Phase 2a complete; Phase 2b ongoing

    Description/Summary:

    ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in a Phase 2a clinical trial, ABX464-101, to treat ulcerative colitis (UC). Patients who completed the induction study had the option to roll over into a 12-month open-label extension study, ABX464-102, in which 22 out of 23 eligible patients were enrolled.

    Read More

    Milestones:

    • Phase 2a data from maintenance study reported in H2 2019
    • Phase 2b trial ongoing
  • Rheumatoid Arthritis Anti-inflammatory
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX464 Phase 2a ongoing

    Description/Summary:

    ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in a completed Phase 2a induction study as well as a 12-month maintenance study in patients with moderate-to-severe ulcerative colitis (UC). In addition to the clinical observations in UC patients, Abivax generated promising pre-clinical data from collagen-induced arthritis animal models.

    Read More

    Milestones:

    • Phase 2a study ongoing
  • Crohn’s Disease Anti-inflammatory
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX464 Phase 2b in preparation

    Description/Summary:

    ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory efficacy in a completed Phase 2a induction study as well as a 12-month maintenance study in patients with moderate-to-severe ulcerative colitis (UC).
    Due the clinical similarities of Crohn’s disease (CD) and UC, and the predictability of the DSS model for both UC and CD, several key opinion leaders (KOLs) are confident that ABX464 will also show beneficial effects in patients suffering from CD.

    Read More

Inflammation and Antiviral

Nothing Found

It seems we can’t find what you’re looking for. Perhaps searching can help.

Antiviral

  • HIV Lasting viral remission
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX464 Phase 2a complete; investigator-initiated trials

    Description/Summary:

    ABX464 is an oral, first-in-class, novel, small molecule inhibiting HIV replication through an entirely new mechanism of action. For the first time in the treatment of HIV, this molecule could reduce or eliminate the viral reservoirs, and thus potentially deliver a long-lasting virological suppression in HIV-patients.

    Read More

    Milestones:

    • Phase 2a data delivered in H1 2018
    • Continued clinical development through investigator-initiated trials
  • Respiratory Syncytial Virus Antiviral drug
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
  • Dengue Antiviral drug
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
  • Influenza Antiviral drug
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3

Cancer

  • Hepatocellular Cancer Immune Enhancer
    • Research
    • Preclinical
    • Phase 1
    • Phase 2
    • Phase 3
    ABX196 in Phase 1/2 POC clinical trial in HCC ongoing

    Description/Summary:

    ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.

    Read More

    Milestones:

    • Phase 1/2 trial ongoing